GADD45G and neoplasm: Ruxolitinib administration resulted in a significant reduction in tumor burden (Fig. 10d), and a prominent elevation of GADD45g expression in hCD45-positive BMMNCs (Fig. 10e), which is consistent with our in vitro observations (Fig. 10a).